Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1828-1835

  Espinel Ingroff, A ^a   Bartlett, M ^c   Chaturvedi, V ^d   Ghannoum, M ^e   Hazen, K C ^b   Pfaller, M A ^f   Rinaldi, M ^g   Walsh, T J ^h  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d New York Department of Health   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; FUNGUS CULTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

EID: 0035007179     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1828-1835.2001     Document Type: Article

References (31)

1. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
2. Chumpitazi, B. F. F., C. Pinel, B. Lebeau, P. Ambroise-Thomas, and R. Grillot. 1999. Aspergillus fumigatus antigen detection in sera from patients at risk for invasive apergillosis. J. Clin. Microbiol. 38:438-443.
3. Clancy, C., and M. H. Nguyen. 1999. Correlation between in vitro susceptibility determined by Etest and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob. Agents Chemother. 43:1289-1290.
4. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillius fumigatus. Antimicrob. Agents Chemother. 41:1364-1368.
5. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.
6. Dismukes, W. E. 2000. Introduction to antifungal drugs. Clin. Infect. Dis. 30:653-657.
7. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
8. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
9. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
10. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
11. Fling-Tomc, J. C., E. Huczo, B. Minassian, and D. P. Bonner. 1998. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42:313-318.
12. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical use. Rev. Infect. Dis. 12:308-329.
13. Gehrt, A., J. Peter, P. A. Pizzo, and T. J. Walsh. 1995. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J. Clin. Microbiol. 33:1302-1307.
14. Iwen, P. C., M. E. Rupp, and S. H. Hinrichs. 1997. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin. Infect. Dis. 24:1178-1184.
15. Iwen, P. C., M. E. Rupp, L. N. Langnas, E. C. Reed, and S. H. Hinrichs. 1998. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of literature. Clin. Infect. Dis. 26:1092-1097.
16. Khan, Z. U., M. Kortom, R. Marouf, R. Chandy, M. G. Rinaldi, and D. A. Sutton. 2000. Bilateral pulmonary aspergilloma caused by an atypical isolate of Aspergillus terreus. J. Clin. Microbiol. 38:2010-2014.
17. Lass-Florl, C., G. Kofler, G. Kropshofer, J. Hermans, A. Kreczy, M. P. Dierich, and D. Niederwieser. 1998. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42:497-502.
18. Lortholary, O., M.-C. Meyohas, B. Dupont, J. Cadranel, D. Salmon-Ceron, D. Peyramond, D. Simonin, and Centre d'Informations et de Soins de l'Immunodeficience Humaine de l'Est Parisien. 1992. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. Am. J. Med. 95:177-186.
19. Lozano-Chiu, M., P. W. Nelson, M. Lancaster, M. A. Pfaller, and J. H. Rex. 1997. Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. J. Clin. Microbiol. 35:270-272.
20. Moore, C. B., N. Sayers, J. Mosquera, J. Slaven, and D. W. Denning. 2000. Antifungal drug resistance in Aspergillus. J. Infect. 41:203-220.
21. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. Nguyen, M. H., and C. Y. Yu. 1999. Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole. J. Clin. Microbiol. 37:141-145.
24. Oakley, K. L., G. Morrissey, and D. W. Denning. 1997. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1504-1507.
25. Odds, F. C., F. V. Gerven, A. Espinel-Ingroff, M. S. Bartlett, M. A. Ghannoum, M. V. Lancaster, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, and T. J. Walsh. 1998. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42:282-288.
26. Pujol, I., J. Guarro, J. Sala, and M. D. Riba. 1997. Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B against Fusarium. Antimicrob. Agents Chemother. 41:808-811.
27. Ribaud, P., P. C. Chastang, J.-P. Latge, L. Baffroy-Lafitte, N. Parquet, A. Devergie, H. Esperou, F. Selimi, V. Rocha, F. Derouin, G. Socie, and E. Gluckman. 1998. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin. Infect. Dis 28:322-330.
28. Rodriguez-Tudela, J. L., and J. V. Martinez-Suarez. 1995. Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. J. Antimicrob. Chemother. 35:1-11.
29. Schett, G., B. Casati, B. Willinger, G. Weinländer, T. Binder, F. Grabenwöger, W. Sperr, K. Geissler, and L. Jäger. 1998. Endocarditis and aortal embolization caused by Aspergillus terreus in a patient with acute lymphoblastic leukemia in remission: diagnosis by peripheral-blood culture. J. Clin. Microbiol. 36:3347-3351.
30. Sutton, A. A., S. E. Sanche, S. G. Revankar, A. W. Fothergill, and M. G. Rinaldi. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37:2343-2345.
31. Verweij, P. E., M. F. Q. van den Bergh, P. M. Rath, B. E. dePauw, A. Voss, and J. F. G. M. Meis. 1999. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J. Clin. Microbiol. 37:16115-1609.